Supriya Lifescience Ltd Q2 FY27 Profit Falls 42% Amid Margin Reset

Supriya Lifescience Ltd reported Q2 FY27 revenue of INR 206.30 crore, up 3.2% year-on-year, while profit after tax fell 42.0% to INR 29.25 crore as EBITDA margin declined to 22.0% from 36.4% a year earlier. The quarter also prompted the company to lower its FY27 EBITDA margin guidance to 23%-25%.

What were Supriya Lifescience Ltd's Q2 FY27 financial results?

Supriya Lifescience Ltd recorded modest revenue growth but a substantial decline in operating profitability during Q2 FY27. Revenue from operations increased to INR 206.30 crore from INR 199.83 crore in Q2 FY26. EBITDA fell to INR 45.40 crore from INR 72.65 crore, while the EBITDA margin contracted by 14.4 percentage points to 22.0%.

Profit after tax stood at INR 29.25 crore, compared with INR 50.43 crore in the corresponding quarter of the previous year. The PAT margin declined to 14.2% from 25.2%. Management said sales during the quarter were affected by regulatory changes in Latin American markets, which reduced demand for certain products.

For the first half of FY27, Supriya Lifescience reported revenue of INR 396.04 crore, a 14.8% increase from INR 344.91 crore in H1 FY26. H1 EBITDA was INR 92.86 crore and PAT was INR 53.29 crore. The H1 EBITDA margin, based on the reported figures, was 23.4%.

Why did Supriya Lifescience Ltd lower its FY27 margin guidance?

Supriya Lifescience Ltd lowered its FY27 EBITDA margin guidance to 23%-25%, citing its current product and geographic mix, the ramp-up of the Ambernath facility, and prevailing raw material and solvent prices. This replaced the earlier 33%-35% range referred to during the earnings call discussion.

The change is material because the company delivered a 22.0% EBITDA margin in Q2 FY27, well below its prior range. Management linked the quarterly performance to regulatory changes in LATAM, where demand for certain products was affected. The company did not provide a quantified split of the impact from regulations, raw materials, solvents, or the Ambernath ramp-up.

The company maintained its stated aim of reaching INR 1,000 crore in revenue by FY27. Its management said the growth outlook is supported by its product pipeline and demand across therapeutic areas including anaesthetics, antidiabetics, anti-anxiety products, vitamins and ADHD products. The stated revenue milestone and the revised margin range show that growth and profitability are being managed against different near-term operating conditions.

How are product launches and Ambernath operations progressing?

Supriya Lifescience Ltd launched two anaesthetic liquid inhalation products from its Ambernath facility during the quarter, adding to its finished dosage product offering. Management said these products are expected to scale up over coming quarters, without providing revenue contributions or a specific ramp-up timeline.

The Ambernath site has commissioned finished dosage capabilities for tablets, capsules, liquids, nasal products, inhalation products and injectables. Commercial manufacturing has begun, and the company has received an exhibit batch order for Rest of the World markets. Validation and registration batches are also underway for dossier submissions.

An EU audit of the Ambernath facility is scheduled for November 2026. The company is also progressing with plans for about two ADHD product launches in FY27. Its existing ADHD product is scaling up with demand from LATAM and Europe, according to management.

Which markets and therapeutic segments drove the business mix?

Europe became Supriya Lifescience Ltd's largest geographical market in Q2 FY27, contributing 43% of revenue, compared with 37% in Q2 FY26. Asia accounted for 36%, followed by LATAM at 12%, North America at 5% and other markets at 4%. Exports represented about 80% of quarterly revenue.

The geographical mix is important because the company identified LATAM regulatory changes as a factor affecting sales for certain products in the quarter. Europe’s higher contribution partly reflects the broader international footprint, but the company did not disclose country-level sales, product-specific revenue, or the exact value of demand affected in LATAM.

In the H1 FY27 therapeutic mix, anaesthetics remained the largest segment at 48% of revenue. Vitamins increased their contribution to 16% from 12% in H1 FY26, while analgesics rose to 6% from 2%. Anti-asthmatics accounted for 8% of H1 revenue, indicating a wider mix beyond the company’s largest category.

What does the quarter mean for investors and operations?

The Q2 FY27 outcome shows that revenue growth did not translate into comparable earnings growth, with EBITDA and PAT both declining year-on-year. For investors, the main disclosed change is the reduction in FY27 EBITDA margin guidance to 23%-25%, following the 22.0% margin recorded in the quarter. No share-price movement or market reaction was provided in the available material.

Supriya Lifescience operates five manufacturing blocks with combined reactor capacity of 932 KLPD across approximately 35,000 square metres of manufacturing area. Capacity utilisation was 73% in H1 FY27. It has continued investments in quality-control laboratories, warehousing, research facilities and related infrastructure.

The company said its backward-integrated model includes 20 products across five therapeutic categories, which represented 74% of H1 FY27 revenue. It also has more than 68 scientists across R&D centres in Ambernath and Lote, with four process patents filed in India. The company targets adding three to four products annually.

Conclusion

Supriya Lifescience Ltd delivered Q2 FY27 revenue growth of 3.2%, but a steep decline in EBITDA and PAT reduced operating and net margins. Regulatory changes affecting demand in LATAM, along with product and geographic mix, Ambernath’s ramp-up, and input-cost conditions, were cited in connection with the lower profitability and revised FY27 margin outlook.

Investors will watch the scheduled November 2026 EU audit at Ambernath, the scale-up of the two new anaesthetic inhalation products, and planned ADHD launches during FY27. Progress toward the company’s INR 1,000 crore FY27 revenue milestone and its ability to operate within the revised 23%-25% EBITDA margin guidance remain the disclosed measures to track.